β | Wald | P | OR | 95% confidence interval | |
---|---|---|---|---|---|
A greater number of individuals with T2D with already prescribed SGLT2ins | − 0.04 | 6.57 | 0.01 | 0.96 | 0.92 to 0.98 |
Barriers – knowledge It is difficult for me to apply the principle of achieving HbA1c target values and determining increased CV risk to one patient | 0.76 | 7.09 | 0.008 | 2.2 | 1.22 to 3.73 |
Barriers – guidelines: | |||||
Familiarity with GLP-1 RAs` side effects | 1.57 | 5.43 | 0.02 | 4.8 | 1.28 to 17.9 |
Familiarity with SGLT2ins` side effects | − 3.41 | 18.5 | < 0.001 | 0.03 | 0.01 to 0.16 |
The new guidelines` protocol that uses a double criterion for assessing the quality of T2D control helps in some cases, in some, it doesn't) vs. (yes, it sure helps) | 1.69 | 7.4 | 0.006 | 5.4 | 1.61 to 18.05 |
Constant | 3.86 | 7.2 | 0.007 |